Home Neglected Parasitic Diseases Drug Development Consortium News Contact
© IP Research Consulting 2014

Neglected infectious diseases

Protozoan parasites are amongst the most common infectious agents in the tropics and  subtropics. The respective diseases are a major cause of morbidity and mortality in many  developing countries and have serious consequences for socio-economic development in  these regions. Primary infections are not the only concern; secondary infections in HIV-  infected and immuno-compromised patients also pose grave health risks. A major problem  associated with these diseases is their prevalence in third world countries which are the least  well-equipped to develop new drugs and invest in R&D.    Leishmaniasis is a worldwide disease, affecting 88 countries. The annual incidence is  estimated at 1-1.5 million cases of CL and 500 000 cases of VL. The overall prevalence of the  disease is 12 million people and the population at risk is 350 million.   Chagas disease occurs throughout Mexico and Central and Southern America, and continues  to pose a serious threat to health in many countries of the region. The overall prevalence of  human T. cruzi infection is estimated at 16-18 million cases. Approximately 120 million people, i.e. 25% of the inhabitants of Latin America, are at risk of contracting the infection.  For African trypanosomiasis, estimates indicate that over 60 million in  250 foci are associated with the risk of contracting the disease, and  there are about 300 000 new cases every year. However, less than 4  million people are under surveillance and only about 40 000 are  diagnosed and treated, due to difficulty of diagnosis and remoteness  of affected areas. These figures are relatively small compared to  other tropical diseases, but African trypanosomiasis, without  intervention, has the propensity to develop into epidemics, making it a  major public health problem with a case fatality rate, in untreated  patients of 100%. Control of trypanosomatid protozoan family is a major challenge not  only in the third world, but increasingly in the western hemisphere, including Europe. The  KINDReD consortium will respond to this global threat through the development of a new  generation of therapeutics for anti-trypanosomal treatment that ultimately will convey  significant benefits for human health world-wide.  The proposed drug development initiative  attains synergy with, and extends, previous FP7 programmes (Leishdrug, Kaladrug,  Trypobase and GameXP). Drawing on this experience and extensive, additional  multidisciplinary expertise from global leaders in academia and industry, KINDReD will bring a  competitive edge to the strategic planning, innovation and development of these much  required new chemical entities.  

Neglected Infectious Diseases

next NID Leishmaniasis Chagas Human African Trypanosomiasis Current Chemotherapy
© IP Research Consulting 2014
Neglected Parasitic Diseases NID